Cancer type
Biliary
Biliary tract cancer.
Must-know
1
ctDNA after resection of extrahepatic cholangiocarcinoma
Yoo et al. Journal of Hepatology. 2025.
In the STAMP adjuvant trial biomarker cohort (89 patients), ctDNA before adjuvant chemotherapy was associated with shorter disease-free survival (hazard ratio 1.8). ctDNA at 12 weeks on treatment had a hazard ratio of 7.72.
A randomized ctDNA-guided biliary trial was not identified. The study below is a biomarker cohort inside the STAMP adjuvant trial.
Listed when a study is a randomized or prospective interventional ctDNA or MRD trial, is cited in NCCN or ESMO guidance, or is a prospective validation cohort in a high-impact journal. Shorter lists mean fewer studies met that rule. No test is ranked.
Publications and presentations
Level 3 · JAMA Network Open · 2025
Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors.
Mahadevia H, et al. PMID 40938601
The study compared mutation concordance between circulating tumor DNA and tissue next-generation sequencing in advanced pancreatobiliary tumors. The abstract does not name a commercial ctDNA assay.
No Colorectal and GI updates are on file for this filter.